Iruplinalkib (WX-0593) is a Chinese innovative ALK/ROS1-TKI, which has shown promising anticancer activity and favorable safety profile among patients with advanced NSCLC harbouring ALK or ROS1 rearrangement. The gene discussed is ALK; the disease is non-small cell lung carcinoma.